We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Boston Scientific Launches Postmarket Registry for Lotus Valve System

Boston Scientific Launches Postmarket Registry for Lotus Valve System

June 5, 2014

Boston Scientific has launched a postmarket registry to assess real-world performance of its Lotus second-generation transcatheter aortic valve implantation System, the Natick, Mass.-based company said Wednesday.

The RESPOND Post Market Registry will collect data on clinical outcomes and device performance in 1,000 patients implanted at 50 medical centers around the world, according to the company. To date, three patients enrolled in the registry have been implanted with the Lotus Valve System.
Follow-up will occur when the patient is discharged, and again at 30 days, 12 months and annually through five years, Boston Scientific says.

The prospective, open-label, multicenter, single-arm, observational postmarket study has a primary endpoint of all-cause mortality compared with a performance goal, plus undisclosed secondary endpoints using Valve Academic Research Consortium guidelines and definitions, the devicemaker says.

An independent lab will analyze the echocardiographic images, and an independent clinical events committee will judge key clinical events — measures designed to increase the quality of data and address inconsistencies with site-reported data, factors that are frequently seen in other postmarket studies, the company notes.

The Lotus system is indicated for patients with severe aortic stenosis who are at high risk for surgical valve replacement. 

The system received CE Mark approval on last October and is available for sale in countries that observe that designation. It remains investigational in the U.S. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.

Medical Devices Postmarket Safety
  • Related Events

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing